8-K: RxSight Reports Q1 2026 Results, Reaffirms Sales Outlook

RxSight, Inc. announced its first quarter 2026 financial results, reporting $30.9 million in sales and maintaining its full-year revenue and gross margin guidance.

Summary

• RxSight reported Q1 2026 sales of $30.9 million, a decrease of 18.5% year-over-year, attributed to lower Light Delivery Device (LDD) unit volumes as expected.
• The company sold 27,472 Light Adjustable Lens (LAL) units and 20 LDDs in the quarter, expanding its installed base to 1,154 LDD units.
• Gross profit margin improved to 76.1% from 74.8% in the prior year, driven by a favorable product mix towards LAL sales.
• Total operating expenses increased to $41.3 million from $39.0 million in Q1 2025, due to expansion of global commercial and support teams.
• The net loss for Q1 2026 was $15.9 million, or $(0.38) per share, compared to a net loss of $8.2 million, or $(0.20) per share, in Q1 2025.
• Adjusted net loss was $(7.9) million, or $(0.19) per share, compared to $(1.1) million, or $(0.03) per share, in the prior year.
• As of March 31, 2026, the company had $217.9 million in cash, cash equivalents, and short-term investments.
• Full-year 2026 guidance remains unchanged for revenue ($120-$135 million) and gross margin (70%-72%), with operating expenses expected at the high end of the previous range ($150-$160 million).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant year-over-year decline in sales and widening net loss, despite reiterated guidance and positive clinical data.

Positives

• Gross profit margin increased to 76.1% in Q1 2026 from 74.8% in Q1 2025, due to a favorable shift in product mix towards LAL sales.
• The company reiterated its full-year 2026 sales guidance of $120 million to $135 million.
• Full-year 2026 gross margin guidance of 70% to 72% was also reiterated.
• Clinical data presented at the ASCRS annual meeting highlighted the versatility and impact of adjustability, with one study showing 93.1% of patients achieving 20/20 or better distance and J1 or better near vision.
• Another meta-analysis demonstrated pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction.
• Regulatory approval was received in New Zealand, expanding the company's international footprint.
• The installed base of Light Delivery Devices (LDDs) expanded to 1,154 units.

Negatives

• Sales decreased by 18.5% to $30.9 million in Q1 2026 compared to $37.9 million in Q1 2025.
• Net loss widened to $15.9 million in Q1 2026 from $8.2 million in Q1 2025.
• Adjusted net loss increased to $7.9 million in Q1 2026 from $1.1 million in Q1 2025.
• Operating expenses increased to $41.3 million in Q1 2026 from $39.0 million in Q1 2025.
• LAL procedures decreased by 0.4% year-over-year.

Risks

• Operating expenses are expected to be at the high end of the previous range ($150 to $160 million) for 2026, reflecting targeted investments in strategic growth initiatives.
• The company's future financial performance is subject to risks and uncertainties, including those detailed in its SEC filings, which could cause actual results to differ materially from forward-looking statements.

Future Outlook

The company reiterates its 2026 financial guidance, projecting revenue between $120 million and $135 million, and a gross margin between 70% and 72%. Operating expenses are anticipated to be at the high end of the previously stated range of $150 million to $160 million, reflecting strategic investments. Non-cash stock-based compensation expense is expected to be between $30 million and $32 million.

Management Comments

• "We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives," said Ron Kurtz, President and Chief Executive Officer of RxSight.
• "As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices."

Industry Context

StockSavvy.ai notes that RxSight's Q1 2026 results reflect a challenging market environment for ophthalmic devices, with sales declining year-over-year. However, the company's focus on its Light Adjustable Lens (LAL) technology and positive clinical data presented at ASCRS suggest a strategic commitment to innovation and differentiation in a competitive landscape.

Comparison to Industry Standards

• The reported gross margin of 76.1% is strong, indicating efficient production and pricing power for its core LAL product, which is a key differentiator in the intraocular lens market.
• The clinical data presented at ASCRS, showing high refractive accuracy (91.2% within 0.50 diopters and 93.1% achieving 20/20 or better vision), sets a high benchmark for adjustable intraocular lens technology.
• Competitors in the IOL market, such as Alcon and Johnson & Johnson Vision, also focus on advanced IOL technologies, but RxSight's adjustability post-surgery remains a unique selling proposition.

Stakeholder Impact

• Shareholders: The widening net loss and declining sales may negatively impact shareholder value in the short term, although reiterated guidance and positive clinical data offer some long-term optimism.
• Employees: Increased operating expenses due to the expansion of global commercial and support teams suggest continued investment in personnel, potentially leading to growth opportunities but also pressure on profitability.
• Customers (Practices): The expansion of the LDD installed base to 1,154 units indicates continued adoption of the technology, which could benefit practices offering customized vision solutions.
• Patients: The positive clinical data on refractive accuracy and visual outcomes reinforces the value proposition of the LAL system for patients seeking customized vision after cataract surgery.

Next Steps

• Continue to refine commercial initiatives.
• Invest in the company's team and pipeline.
• Build momentum across the company.
• Host a conference call on May 6, 2026, to discuss Q1 2026 financial results.

Key Dates

Recommendation

While the company faces headwinds with declining sales and widening losses, the reiterated full-year guidance, strong gross margins, positive clinical data, and international expansion provide a basis for holding the stock. The market will likely await signs of sales stabilization and improved profitability before a more positive outlook can be justified.

Keywords

RxSight, 8-K, Q1 2026 Results, Light Adjustable Lens, Cataract Surgery, Ophthalmic Devices, Financial Results, Sales Outlook